Acute Respiratory InfectionsRESPROTECTNCT06569160

Efficacy of Ultraviolet Germicidal Irradiation Devices to Reduce Respiratory Infections in Nursing Homes: Cluster Randomized Crossover Trial

A study testing Upper-room UVGI (Ultra-Violet Germicidal Irradiation) in people with Acute Respiratory Infections, run by Centre Hospitalier Emile Roux at 12 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

RESPROTECT is a trial aimed at evaluating the effectiveness of upper room ultraviolet devices in reducing the frequency of severe respiratory infections in elderly nursing homes. The study takes place in 12 nursing homes in the center of France. Read more about this study

Who is it for?: Any ageHealthy volunteers can take part
Conditions the study is for: Acute Respiratory Infections
What is being tested?: Upper-room UVGI (Ultra-Violet Germicidal Irradiation)
Type of treatment: Medical device
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 1,687 participants
Where: 12 sitesFrance
Study dates: 1 Oct 2024to 30 Apr 2026
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages Any age
All sexes
Healthy volunteers accepted
Child, Adult, Older adult

Center Inclusion criteria:

Elderly Nursing homes (ENH):

Having a system for monitoring cases of upper and lower respiratory infections among their residents.
Agreeing to take part in the study
Undertaking to comply with the protocol
Accepting the installation of UVGI devices
Undertaking to provide all residents or their legal guardians/curators with an individual information leaflet.

Center Exclusion criteria:

ENH:

Not wishing to be equipped with UVGI devices in all rooms considered necessary to be equipped by the investigators
Having planned a major change to the structure (extension, renovation, closure, requalification, etc.) during the course of the study, which could affect the study population and/or UVGI air treatment devices.

Individual Inclusion criteria:

All residents present in one of the participating ENH at the start of each of the two study periods, or arriving in one of the participating ENH during one of the two periods, will be eligible

Individual Exclusion criteria :

Residents of the ENH included in the study who have expressed (personally or through a relative or legal representative) the wish that their personal data not be used for the study will not be included in the study.

Trial locations and contacts

12 sites in 1 country.

City, postcode or hospital

12 sites in 1 country

France12 sites

EHPAD Notre Dame
Beaulieu, 43021
EHPAD du Centre hospitalier du Pays de Craponne sur Arzon
Craponne-sur-Arzon, 43500
EHPAD Paradis
Espaly-Saint-Marcel, 43000
EHPAD du Centre hospitalier Pierre Gallice
Langeac, 43300
EHPAD Les Terrasses de la Gazeille
Le Monastier-sur-Gazeille, 43150
EHPAD Les Patios du Velay
Le Puy-en-Velay, 43000
EHPAD Nazareth
Le Puy-en-Velay, 43000
EHPAD Saint-Joseph
Le Puy-en-Velay, 43000
EHPAD L'Age d'Or
Monistrol-sur-Loire, 43120
EHPAD Résidence Sigolène
Sainte-Sigolène, 43600
EHPAD Saint Jacques
Saugues, 43170
EHPAD Marie Goy
Vorey, 43800

Other trials in France

About this study

Official title: Impact du déploiement de Dispositifs d'Inactivation Des pathogènes de l'Air Par UVGI Dans la Lutte Contre Les Maladies Respiratoires Touchant Les résidents d'EHPAD

Read the detailed description

The objective of this clinical trial is to determine whether ultraviolet germicidal irradiation (UVGI) can decrease the frequency of severe acute respiratory infections in elderly people living in nursing homes.

12 elderly nursing homes (ENH) will participate in the study. In all the ENHs included, UVGI devices will be installed in upper part under the ceiling of common rooms (refectories, group activity rooms, lounges) at the start of the study. The UVGI devices can be deactivated by installing an invisible internal filter. The inactivation filters will be installed by a technical team independent of the investigation team. Inactivation will therefore be carried out blind to the care givers and the investigation team.

The nursing homes included will be randomized into two arms:

In arm A: the UVGI device will be left active during period 1, and filtered/deactivated during period 2.
In arm B: the UVGI device will be filtered/deactivated during period 1 and left active during period 2.

The two periods will last 7 months each, and will take place two years in a row on the same dates (October 1 to April 30). They will be separated by a 5-month wash-out period (May 1 to September 30), during which all UVGI devices will be switched off in both arms.

The main questions the study aims to answer is: do active UVGI devices decrease the number of acute respiratory infections leading to oxygen therapy, hospitalization or death during the study periods.

Conditions: Acute Respiratory Infections
Being tested: Upper-room UVGI (Ultra-Violet Germicidal Irradiation)
Keywords: Ultraviolet Germicidal Irradiation (UVGI); respiratory infections; nursing homes; elderly; cluster randomized crossover trial
Medical subject headings: Respiratory Tract Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Upper-room UVGI (Ultra-Violet Germicidal Irradiation)Device
Nursing homes are equipped with UVGI devices in all common living places. UVGI devices can be deactivated by installing an invisible internal filter. The inactivation filters will be installed by a technical team independent of the investigation team. Inactivation will therefore be carried out blind to the care givers and the investigation team. The centers included will be randomized into two arms. In arm A: the UVGI device will be left active during period 1, and filtered/deactivated during period 2. In arm B: the UVGI device will be filtered/deactivated during period 1 and left active during period 2.
The two periods will last 7 months each, and will take place two years in a row on the same dates (October 1 to April 30). They will be separated by a 5-month wash-out period (May 1 to September 30), during which all UVGI equipments will be switched off in both arms.

Study groups in NCT06569160
Study group	Role	What they receive
UVGI Active during period 1, UVGI Sham during period 2	Other	Not described Receives: Device: Upper-room UVGI (Ultra-Violet Germicidal Irradiation)
UVGI Sham during period 1, UVGI Active during period 2	Other	Not described Receives: Device: Upper-room UVGI (Ultra-Violet Germicidal Irradiation)

What is being measured

The primary outcome is the main question the study is designed to answer.

Incidence of severe acute symptomatic upper and lower respiratory infections
Acute symptomatic upper and lower respiratory infections include: sinusitis, otitis media, nasopharyngitis, angina, tracheitis, bronchitis, pneumonia, pulmonary abscesses and COPD exacerbations. Symptomatic infection with SARS-Cov-2 will be considered by default as a respiratory infection, even if extra-respiratory symptoms predominate.
Severe acute respiratory infections = acute respiratory infections leading to oxygen therapy, hospitalization or death.
Measured: From enrollment to the end of the second follow-up period (19 months later)

Secondary outcomes (6)

Incidence of acute upper and lower respiratory infections, all grades of severity combined
Acute symptomatic upper and lower respiratory infections include: sinusitis, otitis media, nasopharyngitis, angina, tracheitis, bronchitis, pneumonia, pulmonary abscesses and COPD exacerbations. Symptomatic infection with SARS-Cov-2 will be considered by default as a respiratory infection, even if extra-respiratory symptoms predominate.
Measured: From enrollment to the end of the second follow-up period (19 months later)
Incidence of all-cause hospitalisations or death
All-cause hospitalisations or death include hospitalisation due to acute respiratory infections, hospitalisations due to any other documented or undocumented cause, death to acute respiratory infections, and deaths from any other documented or undocumented cause
Measured: From enrollment to the end of the second follow-up period (19 months later)
Viral and bacterial load in air samples
Air samples collected every 7 weeks in 2 common living areas per center
Measured: From enrollment to the end of the second follow-up period (19 months later)
Viral and bacterial load on fomites samples
Samples collected every 7 weeks in 2 common living areas per center
Measured: From enrollment to the end of the second follow-up period (19 months later)
Incremental Cost-effectiveness ratio
Generated/avoided costs
Measured: From enrollment to the end of the second follow-up period (19 months later)
Incidence of adverse events of interest, overall and by severity grade
Adverse events of interest: keratitis and erythematous skin eruptions in body areas exposed to light
Measured: From enrollment to the end of the second follow-up period (19 months later)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Oct 202430 Apr 2026

First posted23 Aug 2024
Study start1 Oct 2024
Primary completion30 Apr 2026
Study completion30 Apr 2026

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Acute Respiratory InfectionsStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Prevention
Allocation: Randomised
Intervention model: Crossover
Model description: Cluster Randomized Crossover
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 1,687 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06569160
Sponsor's protocol ID: RIPH2_GADEA_RESPROTECT
Other IDs: ID-RCB
Acronym: RESPROTECT
Status last verified: Jul 2026
First submitted: 25 Jul 2024
Last updated: 3 Aug 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Yes: All IPD collected throughout the trial

Publications

Cornille C, Luneau E, Gabillard D, Mathieu M, Lengagne S, Perrin E, Ezzouak M, Gondol F, Peuriere M, Maubert B, Saint-Sardos P, Peghaire S, Blanc FX, Ekouevi DK, Anglaret X, Gadea E. Efficacy of ultraviolet germicidal irradiation (UVGI) devices to decrease the incidence of respiratory infections in nursing homes: study protocol for a cluster randomized crossover trial (RESPROTECT). Trials. 2026 May 20;27(1):493. doi: 10.1186/s13063-026-09797-y.
PubMed 42163326

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
Not yet recruiting
Influence of Patient Positioning During Nasal Lavage
Acute Upper Respiratory Tract Infections, Nasal Obstruction
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)

All Acute Respiratory Infections trials

Study at a glance

From the registry record, last updated by the sponsor on 3 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Impact du déploiement de Dispositifs d'Inactivation Des pathogènes de l'Air Par UVGI Dans la Lutte Contre Les Maladies Respiratoires Touchant Les résidents d'EHPAD
ClinicalTrials.gov ID: NCT06569160
Acronym / sponsor ID: RESPROTECT / RIPH2_GADEA_RESPROTECT
Conditions: Acute Respiratory Infections
Keywords: Ultraviolet Germicidal Irradiation (UVGI); respiratory infections; nursing homes; elderly; cluster randomized crossover trial
Study type: Interventional
Recruitment status: Completed
Enrolment: 1,687 participants (actual)
Lead sponsor: Centre Hospitalier Emile RouxUniversity, hospital or other
Collaborators: ANRS, Emerging Infectious Diseases, University of Bordeaux
Study start: 1 Oct 2024 (actual)
Primary completion: 30 Apr 2026 (actual)
Study completion: 30 Apr 2026 (actual)
First posted: 23 Aug 2024 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

The nursing homes included will be randomized into two arms:

In arm A: the UVGI device will be left active during period 1, and filtered/deactivated during period 2.
In arm B: the UVGI device will be filtered/deactivated during period 1 and left active during period 2.

Study design

Primary purpose: Prevention
Allocation: Randomised
Intervention model: Crossover
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 2
Model description: Cluster Randomized Crossover

Arm	Type	Receives
UVGI Active during period 1, UVGI Sham during period 2	Other	Device: Upper-room UVGI (Ultra-Violet Germicidal Irradiation)
UVGI Sham during period 1, UVGI Active during period 2	Other	Device: Upper-room UVGI (Ultra-Violet Germicidal Irradiation)

Who may qualify

Sex: All
Healthy volunteers: Accepted
Age groups: Child, Adult, Older adult

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Upper-room UVGI (Ultra-Violet Germicidal Irradiation)Nursing homes are equipped with UVGI devices in all common living places. UVGI devices can be deactivated by installing an invisible internal filter. The inactivation filters will be installed by a technical team independent of the investigation team. Inactivation will therefore be carried out blind to the care givers and the investigation team. The centers included will be randomized into two arms. In arm A: the UVGI device will be left active during period 1, and filtered/deactivated during period 2. In arm B: the UVGI device will be filtered/deactivated during period 1 and left active during period 2. The two periods will last 7 months each, and will take place two years in a row on the same dates (October 1 to April 30). They will be separated by a 5-month wash-out period (May 1 to September 30), during which all UVGI equipments will be switched off in both arms.	Device	UVGI Active during period 1, UVGI Sham during period 2, UVGI Sham during period 1, UVGI Active during period 2

Primary outcome

Incidence of severe acute symptomatic upper and lower respiratory infections
Time frame: From enrollment to the end of the second follow-up period (19 months later)
Acute symptomatic upper and lower respiratory infections include: sinusitis, otitis media, nasopharyngitis, angina, tracheitis, bronchitis, pneumonia, pulmonary abscesses and COPD exacerbations. Symptomatic infection with SARS-Cov-2 will be considered by default as a respiratory infection, even if extra-respiratory symptoms predominate. Severe acute respiratory infections = acute respiratory infections leading to oxygen therapy, hospitalization or death.

6 secondary outcomes

Incidence of acute upper and lower respiratory infections, all grades of severity combined
Time frame: From enrollment to the end of the second follow-up period (19 months later)
Incidence of all-cause hospitalisations or death
Time frame: From enrollment to the end of the second follow-up period (19 months later)
Viral and bacterial load in air samples
Time frame: From enrollment to the end of the second follow-up period (19 months later)
Viral and bacterial load on fomites samples
Time frame: From enrollment to the end of the second follow-up period (19 months later)
Incremental Cost-effectiveness ratio
Time frame: From enrollment to the end of the second follow-up period (19 months later)
Incidence of adverse events of interest, overall and by severity grade
Time frame: From enrollment to the end of the second follow-up period (19 months later)

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2026.
Derived from this study: PubMed 42163326Cornille C, Luneau E, Gabillard D, Mathieu M, Lengagne S, Perrin E, Ezzouak M, Gondol F, Peuriere M, Maubert B, Saint-Sardos P, Peghaire S, Blanc FX, Ekouevi DK, Anglaret X, Gadea E. Efficacy of ultraviolet germicidal irradiation (UVGI) devices to decrease the incidence of respiratory infections in nursing homes: study protocol for a cluster randomized crossover trial (RESPROTECT). Trials. 2026 May 20;27(1):493. doi: 10.1186/s13063-026-09797-y.
Protocol publication (Trials 2026, in press)Link provided by the sponsor.
Individual participant dataSharing planned: Yes. All IPD collected throughout the trial

Related trials for Acute Respiratory Infections

Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
Not yet recruiting
Influence of Patient Positioning During Nasal Lavage
Acute Upper Respiratory Tract Infections, Nasal Obstruction
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Cyril CORNILLE, MD principal investigator

Hôpital Emile Roux, le Puy en Velay

12 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing Upper-room UVGI (Ultra-Violet Germicidal Irradiation) in people with Acute Respiratory Infections, run by Centre Hospitalier Emile Roux at 12 sites in France.

The full registered description is in the About this study section and the official record.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of severe acute symptomatic upper and lower respiratory infections (time frame: From enrollment to the end of the second follow-up period (19 months later)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06569160, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2026.